About Us Services Careers FAQ Contact Us 0
Home Pharmaceuticals Animal Vaccine Market Size to Grow at 5.6% CAGR by 2030
Animal Vaccine Market

Animal Vaccine Market Size, Share & Trends Analysis Report By Product Type (Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Conjugate Vaccines, Recombinant Vaccines, DNA Vaccines), By Animal Type (Companion Animal, Livestock Animal, Aquaculture) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2024-2032

Report Code: SRPH1652DR
Last Updated : May 09, 2023
Author : Straits Research
Starting From
USD 2300
Buy Now
File Formats

Table Of Content

  1. Executive Summary
    1. Research Objectives
    2. Limitations & Assumptions
    3. Market Scope & Segmentation
    4. Currency & Pricing Considered
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
    1. Drivers
    2. Market Warning Factors
    3. Latest Macro Economic Indicators
    4. Geopolitical Impact
    5. Technology Factors
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
    1. North America
    2. Europe
    3. APAC
    4. Middle East and Africa
    5. LATAM
  2. ESG Trends
    1. Global Animal Vaccine Market Introduction
    2. By Product Type
      1. Introduction
        1. Product Type By Value
      2. Attenuated Vaccines
        1. By Value
      3. Inactivated Vaccines
        1. By Value
      4. Subunit Vaccines
        1. By Value
      5. Toxoid Vaccines
        1. By Value
      6. Conjugate Vaccines
        1. By Value
      7. Recombinant Vaccines
        1. By Value
      8. DNA Vaccines
        1. By Value
    3. By Animal Type
      1. Introduction
        1. Animal Type By Value
      2. Companion Animal
        1. By Value
      3. Livestock Animal
        1. By Value
      4. Aquaculture
        1. By Value
    1. Introduction
    2. By Product Type
      1. Introduction
        1. Product Type By Value
      2. Attenuated Vaccines
        1. By Value
      3. Inactivated Vaccines
        1. By Value
      4. Subunit Vaccines
        1. By Value
      5. Toxoid Vaccines
        1. By Value
      6. Conjugate Vaccines
        1. By Value
      7. Recombinant Vaccines
        1. By Value
      8. DNA Vaccines
        1. By Value
    3. By Animal Type
      1. Introduction
        1. Animal Type By Value
      2. Companion Animal
        1. By Value
      3. Livestock Animal
        1. By Value
      4. Aquaculture
        1. By Value
    4. U.S.
      1. By Product Type
        1. Introduction
          1. Product Type By Value
        2. Attenuated Vaccines
          1. By Value
        3. Inactivated Vaccines
          1. By Value
        4. Subunit Vaccines
          1. By Value
        5. Toxoid Vaccines
          1. By Value
        6. Conjugate Vaccines
          1. By Value
        7. Recombinant Vaccines
          1. By Value
        8. DNA Vaccines
          1. By Value
      2. By Animal Type
        1. Introduction
          1. Animal Type By Value
        2. Companion Animal
          1. By Value
        3. Livestock Animal
          1. By Value
        4. Aquaculture
          1. By Value
    5. Canada
    1. Introduction
    2. By Product Type
      1. Introduction
        1. Product Type By Value
      2. Attenuated Vaccines
        1. By Value
      3. Inactivated Vaccines
        1. By Value
      4. Subunit Vaccines
        1. By Value
      5. Toxoid Vaccines
        1. By Value
      6. Conjugate Vaccines
        1. By Value
      7. Recombinant Vaccines
        1. By Value
      8. DNA Vaccines
        1. By Value
    3. By Animal Type
      1. Introduction
        1. Animal Type By Value
      2. Companion Animal
        1. By Value
      3. Livestock Animal
        1. By Value
      4. Aquaculture
        1. By Value
    4. U.K.
      1. By Product Type
        1. Introduction
          1. Product Type By Value
        2. Attenuated Vaccines
          1. By Value
        3. Inactivated Vaccines
          1. By Value
        4. Subunit Vaccines
          1. By Value
        5. Toxoid Vaccines
          1. By Value
        6. Conjugate Vaccines
          1. By Value
        7. Recombinant Vaccines
          1. By Value
        8. DNA Vaccines
          1. By Value
      2. By Animal Type
        1. Introduction
          1. Animal Type By Value
        2. Companion Animal
          1. By Value
        3. Livestock Animal
          1. By Value
        4. Aquaculture
          1. By Value
    5. Germany
    6. France
    7. Spain
    8. Italy
    9. Russia
    10. Nordic
    11. Benelux
    12. Rest of Europe
    1. Introduction
    2. By Product Type
      1. Introduction
        1. Product Type By Value
      2. Attenuated Vaccines
        1. By Value
      3. Inactivated Vaccines
        1. By Value
      4. Subunit Vaccines
        1. By Value
      5. Toxoid Vaccines
        1. By Value
      6. Conjugate Vaccines
        1. By Value
      7. Recombinant Vaccines
        1. By Value
      8. DNA Vaccines
        1. By Value
    3. By Animal Type
      1. Introduction
        1. Animal Type By Value
      2. Companion Animal
        1. By Value
      3. Livestock Animal
        1. By Value
      4. Aquaculture
        1. By Value
    4. China
      1. By Product Type
        1. Introduction
          1. Product Type By Value
        2. Attenuated Vaccines
          1. By Value
        3. Inactivated Vaccines
          1. By Value
        4. Subunit Vaccines
          1. By Value
        5. Toxoid Vaccines
          1. By Value
        6. Conjugate Vaccines
          1. By Value
        7. Recombinant Vaccines
          1. By Value
        8. DNA Vaccines
          1. By Value
      2. By Animal Type
        1. Introduction
          1. Animal Type By Value
        2. Companion Animal
          1. By Value
        3. Livestock Animal
          1. By Value
        4. Aquaculture
          1. By Value
    5. Korea
    6. Japan
    7. India
    8. Australia
    9. Taiwan
    10. South East Asia
    11. Rest of Asia-Pacific
    1. Introduction
    2. By Product Type
      1. Introduction
        1. Product Type By Value
      2. Attenuated Vaccines
        1. By Value
      3. Inactivated Vaccines
        1. By Value
      4. Subunit Vaccines
        1. By Value
      5. Toxoid Vaccines
        1. By Value
      6. Conjugate Vaccines
        1. By Value
      7. Recombinant Vaccines
        1. By Value
      8. DNA Vaccines
        1. By Value
    3. By Animal Type
      1. Introduction
        1. Animal Type By Value
      2. Companion Animal
        1. By Value
      3. Livestock Animal
        1. By Value
      4. Aquaculture
        1. By Value
    4. UAE
      1. By Product Type
        1. Introduction
          1. Product Type By Value
        2. Attenuated Vaccines
          1. By Value
        3. Inactivated Vaccines
          1. By Value
        4. Subunit Vaccines
          1. By Value
        5. Toxoid Vaccines
          1. By Value
        6. Conjugate Vaccines
          1. By Value
        7. Recombinant Vaccines
          1. By Value
        8. DNA Vaccines
          1. By Value
      2. By Animal Type
        1. Introduction
          1. Animal Type By Value
        2. Companion Animal
          1. By Value
        3. Livestock Animal
          1. By Value
        4. Aquaculture
          1. By Value
    5. Turkey
    6. Saudi Arabia
    7. South Africa
    8. Egypt
    9. Nigeria
    10. Rest of MEA
    1. Introduction
    2. By Product Type
      1. Introduction
        1. Product Type By Value
      2. Attenuated Vaccines
        1. By Value
      3. Inactivated Vaccines
        1. By Value
      4. Subunit Vaccines
        1. By Value
      5. Toxoid Vaccines
        1. By Value
      6. Conjugate Vaccines
        1. By Value
      7. Recombinant Vaccines
        1. By Value
      8. DNA Vaccines
        1. By Value
    3. By Animal Type
      1. Introduction
        1. Animal Type By Value
      2. Companion Animal
        1. By Value
      3. Livestock Animal
        1. By Value
      4. Aquaculture
        1. By Value
    4. Brazil
      1. By Product Type
        1. Introduction
          1. Product Type By Value
        2. Attenuated Vaccines
          1. By Value
        3. Inactivated Vaccines
          1. By Value
        4. Subunit Vaccines
          1. By Value
        5. Toxoid Vaccines
          1. By Value
        6. Conjugate Vaccines
          1. By Value
        7. Recombinant Vaccines
          1. By Value
        8. DNA Vaccines
          1. By Value
      2. By Animal Type
        1. Introduction
          1. Animal Type By Value
        2. Companion Animal
          1. By Value
        3. Livestock Animal
          1. By Value
        4. Aquaculture
          1. By Value
    5. Mexico
    6. Argentina
    7. Chile
    8. Colombia
    9. Rest of LATAM
    1. Animal Vaccine Market Share By Players
    2. M&A Agreements & Collaboration Analysis
    1. Anicon Labor GmbH
      1. Overview
      2. Business Information
      3. Revenue
      4. ASP
      5. SWOT Analysis
      6. Recent Developments
    2. Boehringer Ingelheim GmbH
    3. Ceva Sante Animale
    4. Hygieia Biological Laboratories
    5. Merck & Co., Inc
    6. Romvac Company S.A.
    1. Research Data
      1. Secondary Data
        1. Major secondary sources
        2. Key data from secondary sources
      2. Primary Data
        1. Key data from primary sources
        2. Breakdown of primaries
      3. Secondary And Primary Research
        1. Key industry insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
    1. Discussion Guide
    2. Customization Options
    3. Related Reports
  3. Disclaimer

Related Reports

Global Report
The global meningococcal vaccine market size was valued at USD 2.76 billion in 2022. It is estimated to reach USD 6.14 billion by 2031, growing at a CAGR of 9.3% during the forecast period (2023–2031). Invasive meningococcal disease (IMD) is a
Buy Now
Global Report
Viral Vaccines Market Size The global viral vaccines market size was valued at USD 55.07 billion in 2024 and is projected to grow from USD 57.72 billion in 2025 to reach USD 79.27 billion by 2033, growing at a 
Buy Now

Purchase Benefits

  • Eligible for a free updated report next year
  • Completely customizable scope
  • 30% discount on your next purchase
  • Dedicated account manager
  • Query resolution within 24 hours
  • Permission to print the report

We are featured on :

www.straitsresearch.com
© Copyright 2025. All rights Reserved.